Long‐term complications in uniformly treated paediatric Langerhans histiocytosis patients disclosed by 12 years of follow‐up of the JLSG‐96/02 studies
Kenichi Sakamoto, Akira Morimoto, Yoko Shioda, Toshihiko Imamura, Shinsaku Imashuku, the Japan LCH Study Group (JLSG)
Abstract
Langerhans cell histiocytosis (LCH) is a rare inflammatory myeloid neoplasia derived from immature myeloid dendritic cells with the mitogen-activated protein kinase (MAPK) pathway gene mutation. LCH is rarely fatal, but patients develop various permanent consequences (PCs). We report the frequencies of LCH-related PCs in paediatric patients (n = 317) treated by the JLSG-96/02 AraC-containing regimens. One-third of LCH patients had at least one PC at a median follow-up of 12 years. Central nervous system (CNS)-related PCs (neurological and endocrinological) accounted for 21·5%, non-CNS-related 16·7%. We require novel therapeutic measures to further reduce the frequency of LCH-related PCs.